Belite Bio Inc ADR (BLTE)
Belite Bio Inc ADR is a depositary receipt listed on NASDAQ that represents common stock of Belite Bio, Inc. Belite Bio is a clinical-stage biopharmaceutical company focused on researching and developing therapies for retinal degenerative eye diseases with unmet medical needs in the United States. Its lead candidate, Tinlarebant (LBS-008), is an oral treatment in phase 3 testing for stargardt disease type 1 and geographic atrophy. The company is also advancing LBS-009, an oral anti-retinol-binding protein 4 therapy in preclinical development for conditions including liver disease, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. Belite Bio was founded in 2016 and is based in San Diego, California, and it operates as a subsidiary of Lin Bioscience International Ltd.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BLTE
|
$160.29
|
1.1% Upside
|
Fair
|
$210.50
|
32.8% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-69.0x
|
7.8x
|
—
|
6.013 B
|
5.739 B
|
0.0%
|
46.9%
|
233.3
|
—
|
41.2%
|
